It is an inhibitor of the enzyme janus kinase 1 (JAK1) and janus kinase 3 (JAK 3), which means that it interferes with the JAK-STAT signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA transcription. In a mouse model of established arthritis,<unk>  rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. This efficacy in this disease model correlated with the inhibition of both JAK1 and JAK3 signaling pathways, suggesting that<unk>  may exert therapeutic benefit via pathways that are not exclusive to inhibition of JAK3.
Tofacitinib
Ocrelizumab
Belatacept
Etanercept
Ibalizumab
Sarilumab
Theralizumab
Atezolizumab